Tavin-EM (Tenofovir disoproxil fumarate + Emtricitabine)

Tenofovir disoproxil fumarate + Emtricitabine
Contact us for more information
Цвет:
Вариант:
Wishlist Compare
Emcure Pharmaceuticals Ltd

Tavin-EM (Tenofovir disoproxil fumarate + Emtricitabine)

ManufacturerEmcure Pharmaceuticals LtdBrand nameTavin-EMActive substanceTenofovir Disoproxil Fumarate + EmtricitabineStrength300mg + 200mgCategoryHIVManufacturerEmcure Pharmaceuticals Ltd

Description  of  Tavin-EM (Tenofovir Disoproxil Fumarate 300mg + Emtricitabine 200mg)

Tavin-EM (Tenofovir Disoproxil Fumarate 300mg + Emtricitabine 200mg) is a combination of three active ingredients (Emtricitabine + Tenofovir) is used alone or with other antiviral drug for the treatment of HIV infection. Tavin-EM (Tenofovir Disoproxil Fumarate 300mg + Emtricitabine 200mg) will not cure or prevent HIV/AIDS. Tavin-EM (Tenofovir Disoproxil Fumarate 300mg + Emtricitabine 200mg) suppresses the HIV replication of virus cell and despite the destruction of the immune system. Tavin-EM (Tenofovir Disoproxil Fumarate 300mg + Emtricitabine 200mg) may help to delay the problems arises from AIDS/HIV diseases. The medicine allowed purchasing only with doctors prescription.

INDICATIONS of  Tavin-EM (Tenofovir Disoproxil Fumarate 300mg + Emtricitabine 200mg)

Tavin-EM (Tenofovir Disoproxil Fumarate 300mg + Emtricitabine 200mg) with combination of antiretroviral drug or alone medicine is indicated for the treatment of HIV-1 infection in adult and children 12yrs / >12yrs.

MECHANISM OF ACTION  of  Tavin-EM (Tenofovir Disoproxil Fumarate 300mg + Emtricitabine 200mg)

An acyclic nucleoside phosphonate di ester associate of adenosine monophosphate is Tenofovir Disoproxil Fumarate ( Tavin-EM (Tenofovir Disoproxil Fumarate 300mg + Emtricitabine 200mg)), that hydrolysed to Tenofovir, finally cellular enzymes phosphorylated to form Tenofovir diphosphate, an restrict chain terminator. Tenofovir contains with DNA fusion of HIV via aggressive prevention of reverse transcriptase and fusion into viral DNA. Tenofovir also inhibits hepatitis B virus polymerase, resulting in blockage of viral replication. Emtricitabine (Tavin-EM (Tenofovir Disoproxil Fumarate 300mg + Emtricitabine 200mg)) is a synthetic nucleoside coordinate of cytidine, which go through phosphorylation occurring inside a cell to Emtricitabine 5'-triphosphate, then take part with deoxycytidine 5'-triphosphate and is integrated into viral DNA which causes chain termination. The drug shows activity against HIV-1, HIV-2 viruses and hepatitis B virus (HBV).

Absorption of Tavin-EM (Tenofovir Disoproxil Fumarate 300mg + Emtricitabine 200mg)

Tenofovir ( Tavin-EM (Tenofovir Disoproxil Fumarate 300mg + Emtricitabine 200mg) ) absorbed immediately from the GI tract, bioavailability with high fat meal is approx 25% and duration of peak plasma concentration (PPC) is 1-2hr. In Emtricitabine ( Tavin-EM (Tenofovir Disoproxil Fumarate 300mg + Emtricitabine 200mg) ) , bioavailability is 93%(capsule) and solution 75%, PPC is 1-2 hrs.


Distribution of Tavin-EM (Tenofovir Disoproxil Fumarate 300mg + Emtricitabine 200mg)
Tenofovir( Tavin-EM (Tenofovir Disoproxil Fumarate 300mg + Emtricitabine 200mg) ) volume of distribution is 1.2-1.3 L/kg and plasma protein binding is <1%, In Emtricitabine ( Tavin-EM (Tenofovir Disoproxil Fumarate 300mg + Emtricitabine 200mg) ) independent of concentration and protein binding is <4%.


Metabolism of Tavin-EM (Tenofovir Disoproxil Fumarate 300mg + Emtricitabine 200mg)
Tenofovir Disoproxil Fumarate (Tavin-EM (Tenofovir Disoproxil Fumarate 300mg + Emtricitabine 200mg) , that hydrolysed to Tenofovir, finally cellular enzymes phosphorylated to form Tenofovir diphosphate, an restrict chain terminator. In Emtricitabine ( Tavin-EM (Tenofovir Disoproxil Fumarate 300mg + Emtricitabine 200mg) ) is limited metabolism.


Elimination of Tavin-EM (Tenofovir Disoproxil Fumarate 300mg + Emtricitabine 200mg)
Tenofovir ( Tavin-EM (Tenofovir Disoproxil Fumarate 300mg + Emtricitabine 200mg) ) excreted through urine by active glomerular filtration and tubular secretion and half life is 18hr. Emtricitabine ( Tavin-EM (Tenofovir Disoproxil Fumarate 300mg + Emtricitabine 200mg) eliminated highly unchanged in urine and low limit in faeces, half life is 10hr.

 SIDE EFFECTS  of  Tavin-EM (Tenofovir Disoproxil Fumarate 300mg + Emtricitabine 200mg)

Major effects: Lactic acidosis, severe hepatomegaly with steatosis Renal effects: Nephritis, Nephrogenic, diabetes insipidus, renal failure GI events: Anorexia, abdominal distention, diarrhea, dyspepsia, flatulence Common effects: vertigo, fatigue, raised liver enzyme, athralgia,rhabdomyolysis, osteomalacia.

PRECAUTION  of  Tavin-EM (Tenofovir Disoproxil Fumarate 300mg + Emtricitabine 200mg)

Prior to administration of Tavin-EM (Tenofovir Disoproxil Fumarate 300mg + Emtricitabine 200mg), Patients should take care of these caution as follows :
Patient with hepatomegaly or other serious factors for liver disease, Renal impairment, Pregnancy. Patient Counseling: This drug may cause dizziness, if affected, do not drive or operate machinery. Monitoring Parameters: Check the renal function and serum phosphate concentrations before start of the treatment, 4 weekly during the 1st week, and then 3 monthly. Hepatic function for several months following discontinuation. Determine HIV status in all hepatitis B virus (HBV) infected patients before the treatment.

DRUG INTERACTION  of  Tavin-EM (Tenofovir Disoproxil Fumarate 300mg + Emtricitabine 200mg)

 Prior to administration of Tavin-EM (Tenofovir Disoproxil Fumarate 300mg + Emtricitabine 200mg), Patients should take care of these caution as follows: Patient with hepatomegaly or other serious factors for liver disease, Renal impairment, Pregnancy. Patient Counseling: This drug may cause dizziness, if affected, do not drive or operate machinery. Monitoring Parameters: Check the renal function and serum phosphate concentrations before start of the treatment, 4 weekly during the 1st week, and then 3 monthly. Hepatic function for several months following discontinuation. Determine HIV status in all hepatitis B virus (HBV) infected patients before the treatment.

CONTRAINDICATION  of  Tavin-EM (Tenofovir Disoproxil Fumarate 300mg + Emtricitabine 200mg)

Tavin-EM (Tenofovir Disoproxil Fumarate 300mg + Emtricitabine 200mg) contraindicated in patient with hypersensitivity to Efavirenz. When co administration with voriconazole, Tavin-EM (Tenofovir Disoproxil Fumarate 300mg + Emtricitabine 200mg) is contraindicated and lactation patient is also contraindicated with Viraday

PREGNANCY  of Tavin-EM (Tenofovir Disoproxil Fumarate 300mg + Emtricitabine 200mg)

 ( Tavin-EM (Tenofovir Disoproxil Fumarate 300mg + Emtricitabine 200mg) ) has category B: Animal studies have been developed adverse effect, but sufficient and well-tolerated studies in pregnant women which have failed to develop a risk to the fetus in all trimester in pregnancy. 

DOSAGE of  Tavin-EM (Tenofovir Disoproxil Fumarate 300mg + Emtricitabine 200mg)

  1. Before begin the treatment using with Tavin-EM (Tenofovir Disoproxil Fumarate 300mg + Emtricitabine 200mg), patient should be examine thoroughly for presence of HBV infection or not. Hepatic function test & renal function test should be monitored.
    2. Patients receiving Tavin-EM (Tenofovir Disoproxil Fumarate 300mg + Emtricitabine 200mg) for PrEP, screening the HIV-1 infection for once three months. Dosage recommendation; The advised dose of Tavin-EM (Tenofovir Disoproxil Fumarate 300mg + Emtricitabine 200mg) for adults & pediatric with weight of at least 35kg is one tablet should be administered as once daily by taking with food or without food. For PrEP condition; One Tenvir EM Tavin-EM (Tenofovir Disoproxil Fumarate 300mg + Emtricitabine 200mg) tablet should be taken as once daily for both adults & pediatric with weight of at least 35kg. Dosage adjustment for renal impaired patients; CrCl ≥50ml/min, one tablet should be taken for every 24 hours CrCl 30 to 49ml/min, one Tenvir EM Tavin-EM (Tenofovir Disoproxil Fumarate 300mg + Emtricitabine 200mg) tablet should be taken for every 48 hours CrCl <30ml/min, Tavin-EM (Tenofovir Disoproxil Fumarate 300mg + Emtricitabine 200mg)tablet should not be recommended


STORAGE  of  Tavin-EM (Tenofovir Disoproxil Fumarate 300mg + Emtricitabine 200mg)

Tavin-EM (Tenofovir Disoproxil Fumarate 300mg + Emtricitabine 200mg) store at temperature of 15-30℃.

Tavin-EM (Tenofovir Disoproxil Fumarate 300mg + Emtricitabine 200mg) store with caution and proper label.

Tavin-EM (Tenofovir Disoproxil Fumarate 300mg + Emtricitabine 200mg) store in a cool and dry place.

Tavin-EM (Tenofovir Disoproxil Fumarate 300mg + Emtricitabine 200mg) should keep in children resistance place.

Tavin-EM (Tenofovir Disoproxil Fumarate 300mg + Emtricitabine 200mg) should used before expiry date.

MISSED DOSE of  Tavin-EM (Tenofovir Disoproxil Fumarate 300mg + Emtricitabine 200mg)

Tavin-EM (Tenofovir Disoproxil Fumarate 300mg + Emtricitabine 200mg)  is contains two drugs which is used as once daily. If patients fail to take the dose, must get advice from medical practitioner and follow the instructions. Patient maintain the regular dosing schedule for avoiding the over dosage problem.

Brand name:
Tavin-EM
Active substance:
Tenofovir Disoproxil Fumarate + Emtricitabine
Strength:
300mg + 200mg
Category:
HIV
Manufacturer:
Emcure Pharmaceuticals Ltd
Packaging:
30 Tablet
Product form:
Tablet

No reviews found

Write feedback
Worldwide delivery

Our company ships from India to all countries of the world.

Genuine and Authentic products

All products supplied from the manufacturer of WHO : GMP certified facilities and ISO Certified facilitates

Economical and Affordable prices

All the products are supplying from manufacturing companies of India